Clinical trialPhase 2Withdrawn
Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
- Outcome
- Stopped earlyStudy is being abandoned. (Other)
- Phase
- Phase 2
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- 1 July 2019
- Planned end
- 1 January 2023
- Enrollment
- 0 participants
- Sites
- 1
- Primary outcomes
- Local control rate among PDAC patients treated with neoadjuvant chemotherapy followed by SBRT
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 17 October 2019
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to research the effects of delivering full-dose neoadjuvant multi-agent chemotherapy (folfirinox) followed by stereotactic body radiation therapy (SBRT) in patients with resectable pancreatic ductal adenocarcinoma (PDAC) in order to intensify local therapy and improve outcomes.
Detailed description public domain (ClinicalTrials.gov)
Primary Objectives: 1\. To assess one-year local control rates in patients with operable PDAC who receive neoadjuvant chemotherapy and SBRT Secondary Objectives: 1. To assess the following disease control endpoints: pathological response, disease-free survival, overall survival, failure pattern (local vs. distant) and time to development of distant metastases 2. To assess safety of the SBRT regimen Exploratory objectives 1. To obtain exploratory data correlating tumor response grade with changes in circulating tumor DNA levels following chemotherapy, SBRT, and surgery in patients with PDAC 2. To obtain exploratory data correlating circulating tumor DNA (ctDNA) changes with disease control endpoints (overall survival, disease-free survival, failure pattern, and time to development of distant metastases) 3. To obtain exploratory data on positron emission tomography (PET) and magnetic resonance imaging (MRI) findings and correlations with tumor response among patients treated on study.